Cork University Hospital
- Address
- Wilton, T12 DC4A Cork, Ireland
Oncology (Neoplasms)
Cork University Hospital’s oncology program is testing innovative therapies for breast cancer. It also evaluates new approaches for lung cancer and advances treatment options for other solid tumours.
- Breast cancer
- Lung cancer
- Prostate cancer
- Ovarian cancer
- Colorectal cancer
- Bladder cancer
- Melanoma
- Head and neck cancer
- Gastric cancer
- Urothelial carcinoma
Trials focus on evaluating targeted agents, immunotherapies and adjuvant strategies to improve survival and quality of life for patients with these malignancies.
Hematology & Blood Disorders
The department conducts studies on blood‑related cancers, including acute lymphoblastic leukaemia and multiple myeloma, aiming to discover more effective treatments.
- Acute lymphoblastic leukaemia
- Acute myeloid leukaemia
- Mantle cell lymphoma
- Multiple myeloma
- Myelodysplastic syndromes
- Polycythemia vera
- Myelofibrosis
- Chronic lymphocytic leukemia
- AL amyloidosis
Research includes novel antibodies, cellular therapies and disease‑modifying agents to enhance remission rates and reduce relapse.
Respiratory and Infectious Diseases
Clinical trials address chronic lung conditions such as asthma and chronic obstructive pulmonary disease, as well as emerging infections like COVID‑19.
- Asthma
- Chronic obstructive pulmonary disease
- Cystic fibrosis
- COVID‑19
- Mpox infection
- Severe eosinophilic asthma
- Bronchiectasis
- Idiopathic pulmonary fibrosis
- Respiratory tract infection
The aim is to improve lung function, reduce exacerbations, and evaluate antiviral or anti‑inflammatory therapies for better patient outcomes.
Renal and Urogenital Research
Studies target kidney diseases, with a focus on reducing proteinuria in conditions like IgA nephropathy and exploring treatments for primary membranous nephropathy.
- IgA nephropathy
- Primary membranous nephropathy
- Nephrotic syndrome
- Renal cell carcinoma
- Venous thromboembolism in cancer patients
- Kidney disease associated with multiple myeloma
These trials aim to preserve renal function, decrease protein loss and assess the safety of emerging therapies.
Immune System and Autoimmune Disorders
Research includes inflammatory and autoimmune conditions such as polymyalgia rheumatica and atopic dermatitis, testing new biologic agents.
- Polymyalgia rheumatica
- Atopic dermatitis
- Eosinophilic asthma
- Systemic mastocytosis
- Other immune‑mediated diseases
The goal is to evaluate efficacy of immune‑modulating drugs and improve symptom control and disease remission.
Female Urogenital and Reproductive Health
Trials focus on gynecologic cancers, including ovarian cancer and cervical cancer, to develop better targeted and adjuvant therapies.
- Ovarian cancer
- Fallopian tube cancer
- Cervical cancer
- Endometrial cancer
- High‑risk HER2‑positive breast cancer (female cohort)
- Pregnancy‑related complications
These studies aim to improve survival, reduce recurrence and personalize treatment for women affected by these conditions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 4 of 14 therapeutic areas and 15 of 244 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 238 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 42 by active trials.
- 1Merck Sharp & Dohme LLC7active
lock +41 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1Merck Sharp & Dohme LLC17trials
lock +27 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 45 other sites in Ireland
Therapeutic Area Benchmark — Ireland
Select a therapeutic area to compare against other sites in Ireland.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Ireland
Market Share
Country: Ireland
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Cork University Hospital
lock Showing 1 of 130 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| (Summit) A Multi-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Clinical Study of the Safety and Efficacy of CGT9486 in Subjects with NonAdvanced Systemic Mastocytosis | Cogent Biosciences Inc. | Phase II | Not Recruiting | Apr 2023 | — |
IMP list
lock Showing 1 of 244 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Pembrolizumab | 22 | Unknown | 2015-11-06 | 2026-01-26 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.